Algert Global LLC Acquires 268,612 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Algert Global LLC raised its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 216.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 392,902 shares of the company’s stock after acquiring an additional 268,612 shares during the quarter. Algert Global LLC owned about 0.86% of Amphastar Pharmaceuticals worth $10,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Amphastar Pharmaceuticals by 382.9% in the third quarter. Arrowstreet Capital Limited Partnership now owns 392,310 shares of the company’s stock worth $10,455,000 after acquiring an additional 311,071 shares during the period. UBS Group AG lifted its holdings in shares of Amphastar Pharmaceuticals by 367.2% in the third quarter. UBS Group AG now owns 312,274 shares of the company’s stock worth $8,322,000 after buying an additional 245,440 shares in the last quarter. Bridgeway Capital Management LLC grew its stake in Amphastar Pharmaceuticals by 267.0% during the third quarter. Bridgeway Capital Management LLC now owns 312,337 shares of the company’s stock valued at $8,324,000 after acquiring an additional 227,225 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in Amphastar Pharmaceuticals by 81.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 469,492 shares of the company’s stock worth $10,780,000 after acquiring an additional 210,511 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in Amphastar Pharmaceuticals by 209.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 222,019 shares of the company’s stock worth $5,917,000 after acquiring an additional 150,330 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Insider Buying and Selling

In related news, EVP Rong Zhou sold 9,787 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total transaction of $256,419.40. Following the transaction, the executive vice president owned 138,043 shares in the company, valued at $3,616,726.60. The trade was a 6.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 27.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on AMPH. Barclays started coverage on Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 target price for the company. Needham & Company LLC cut their price objective on Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating for the company in a report on Friday, February 27th. Wells Fargo & Company decreased their price objective on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average price target of $29.50.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $18.17 on Monday. The firm has a market cap of $824.37 million, a P/E ratio of 8.95, a P/E/G ratio of 1.52 and a beta of 0.93. The firm’s fifty day moving average is $25.76 and its 200 day moving average is $26.21. Amphastar Pharmaceuticals, Inc. has a 52 week low of $17.03 and a 52 week high of $31.26. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.90 and a current ratio of 4.02.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.24). The business had revenue of $183.11 million for the quarter, compared to analysts’ expectations of $190.48 million. Amphastar Pharmaceuticals had a net margin of 13.63% and a return on equity of 17.58%. Research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.